Deep search
Profile Picture
  • All
  • Search
  • Copilot
  • Images
  • Videos
  • Maps
  • News
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Past 7 days
    • Any time
    • Past hour
    • Past 24 hours
    • Past 30 days

News

The Lancet2d
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Copyright: © 2015 Elsevier Ltd. Published by Elsevier Ltd.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

To pardon reality TV stars
NPR sues Trump admin
CDC ends recommendation
Man grabs gun, shoots self
Rick Derringer dies at 77 
Boil-water advisory issued
Ohio deputy shot, killed
Rejects Native American suit
Supreme Court declines case
Driver arrested on suspicion
To cut federal contracts
Fort Stanton wildfire
China chemical plant blast
AMAs 2025 winners
Sales in Europe plunge
Scales Everest for 31st time
'Harry Potter' TV series cast
Ending free checked bags
US to have control in deal
Launches AL governor bid
Houston power outage
On meeting Abrego Garcia?
Halts student visa interviews
Machinists end 3-week strike
3 more inmates captured
La Sasso wins NCAA title
To acquire Informatica
Consumer confidence rises
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy